Kadcyla wins EU marketing approval triggering milestone payment for ImmunoGen

|By:, SA News Editor

Roche (RHHBY -0.4%) and ImmunoGen's (IMGN +1.8%) Kadcyla gets European marketing approval, triggering a $5M milestone payment to IMGN.

The drug is approved for adults with "HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received Herceptin and a taxane, separately or in combination." (PR)

The news was expected after the CHMP gave the drug a positive opinion back in September.